Global X Uranium ETF vs GeneDx Holdings Corp — how do they compare? Global X Uranium ETF trades at $46.9, while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). Which is the better fit depends on your goals.
| URA | WGS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $61.81 | $167.51 |
52-Week Low | $37.52 | $34.51 |
Market Cap | — | $2.56B |
Enterprise Value | — | $2.60B |
Signals from Pluang's Aura AI — not financial advice
URA (Global X Uranium ETF) trades at $47.50, up 3.13% today, with strong bullish technical signals from moving averages. The ETF benefits from growing nuclear energy demand driven by AI power needs and government support, including recent $17.5 billion in U.S. reactor funding. However, key financial ratios remain unavailable, and the sector faces volatility from uranium price fluctuations and regulatory shifts.
Outlook remains positive due to structural tailwinds in nuclear energy, but investors should monitor uranium contract pricing and ETF expense ratios. Near-term resistance sits at $48-$50, with support at $45-$47. Risks include policy changes and miner concentration, though institutional interest in nuclear ETFs is rising.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Trailing returns across standard periods
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →